Pharmaceutical formulations

A solid composition comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof wherein the proportion of tenofovir alafenamide or a pharmaceutically acceptable salt thereof in the composition is from about 2.5% to about 12% by weight.

A solid composition comprising from about 2% to about 4% by weight tenofovir alafenamide hemifumarate.

A solid composition comprising from about 5% to about 15% by weight tenofovir alafenamide hemifumarate.

The solid oral dosage form or composition of any one of the preceding claims, wherein the dosage form or composition is a tablet.

A composition comprising (a) tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and (b) emtricitabine or a pharmaceutically acceptable salt thereof, where the total quantity of degradation products derived from the tenofovir alafenamide or the pharmaceutically acceptable salt thereof is less than 3% after storage for one month at 40° C./75% RH in open conditions.

A composition comprising (a) tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and (b) emtricitabine or a pharmaceutically acceptable salt thereof, where the total quantity of degradation products derived from the tenofovir alafenamide or the pharmaceutically acceptable salt thereof is less than 2.5% after storage for three months at 40° C./75% RH in closed conditions.

A composition comprising (a) tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and (b) emtricitabine or a pharmaceutically acceptable salt thereof, where the total quantity of degradation products derived from the tenofovir alafenamide or the pharmaceutically acceptable salt thereof is less than 2% after storage for twelve months at 30° C./75% RH in closed conditions.

A method of producing a solid oral dosage form, composition or tablet of any one of the preceding claims.

A dry granulated mixture of (a) tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and (b) emtricitabine or a pharmaceutically acceptable salt thereof.

A solid oral dosage form, composition or tablet according to any one of the preceding claims for use in the therapeutic treatment of an HIV infection.

A method of therapeutic treatment of an HIV infection comprising administering to a subject a solid oral dosage form, composition or tablet according to any one of the preceding claims.

A method of preventing HIV infection comprising administering to a subject a solid oral dosage form, composition or tablet according to any one of the preceding claims.